Clinical trial
Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance
NCT03833934
Drugs and interventions used in this trial
0 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No interventions are currently published for this study in CureCurrent. View the original registry record below.
Study at a glance
Registry-backedStudy of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance
Design: OBSERVATIONAL · Status: COMPLETED · Phase: Not specified
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Interventions
Sponsors & collaborators
Addario Lung Cancer Medical Institutelead sponsor
Dana-Farber Cancer Institutecollaborator
National Cancer Institute (NCI)collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03833934 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.